Non-synonymous sequence variants within the oxygen-dependent degradation domain of the HIF1A gene are not associated with pre-eclampsia in the Finnish population by Heino, Sanna et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Non-synonymous sequence variants within the oxygen-dependent 
degradation domain of the HIF1A gene are not associated with 
pre-eclampsia in the Finnish population
Sanna Heino1, Milja Kaare2, Sture Andersson3,4 and Hannele Laivuori*1,5
Address: 1Department of Medical Genetics, Haartman Institute, FI-00014 University of Helsinki, Finland, 2Folkhälsan Institute of Genetics, FI-
00014 University of Helsinki, Finland, 3Hospital for Children and Adolescents, Helsinki University Central Hospital, FI-00029 Finland, 
4Department of Pediatrics, FI-00014 University of Helsinki, Finland and 5Department of Clinical Genetics, Helsinki University Central Hospital, 
FI-00029 HUS, Finland
Email: Sanna Heino - sanna.heino@helsinki.fi; Milja Kaare - milja.kaare@helsinki.fi; Sture Andersson - sture.andersson@hus.fi; 
Hannele Laivuori* - hannele.laivuori@helsinki.fi
* Corresponding author    
Abstract
Background: Reduced placental perfusion predisposes to the maternal syndrome pre-eclampsia
characterized by systemically reduced perfusion. Considerable data support the role of angiogenic
factors in the development of the maternal syndrome. Hypoxia-inducible factor (HIF-1) mediates
the cellular responses to hypoxia e.g. by promoting angiogenesis.
Methods: Here we studied whether two single nucleotide sequence variants, c.1744 C>T that
changes residue 582 of HIF-1α from proline to serine (P582S) and c.1762 G>A that changes residue
588 of HIF-1α from alanine to threonine (A588T) in the exon 12 of the HIF1A gene, are associated
with pre-eclampsia. We studied 108 women with pre-eclampsia in their first pregnancy, and 101
controls with normotensive pregnancies. Pre-eclampsia was defined as a blood pressure level of at
least 140/90 mmHg in a woman who was normotensive before 20 weeks of gestation, and
proteinuria at least of 0.3 g per 24-hour urine collection. The patients and controls were genotyped
for variations in the exon 12 of HIF1A gene by sequencing
Results:  The frequencies of the c.1744 C>T and c.1762G>A sequence variants were not
significantly different between women with pre-eclamptic first pregnancies and women with
normotensive pregnancies. In addition, two synonymous variants (c.1740G>A and c.1800A>T)
were detected at comparable levels in the two groups. All variants were identified in the
heterozygous form.
Conclusion: The sequence variants in the exon 12 of the HIF1A gene were not associated with
pre-eclampsia in the Finnish population.
Background
Pre-eclampsia, a pregnancy-specific vascular disorder,
complicates 3% of pregnancies, and it may threaten the
survival of both mother and baby [1]. The onset and clin-
ical course is unpredictable and there are currently no pre-
dictive tests or preventive means available in clinical
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practice. Pre-eclampsia resolves after delivery, which is
currently the only existing therapy. It is a heterogeneous
disease, commonly mixed presentation of two categories:
placental pre-eclampsia with origins primarily in abnor-
mal placental perfusion and maternal pre-eclampsia with
origins primarily in pre-existing problems in the mother
[2]. Pre-eclampsia shares many common risk factors with
atherosclerosis, such as pre-existing hypertension, diabe-
tes, obesity, renal disease and the metabolic syndrome [3].
A large body of evidence also suggests that pre-eclampsia
is associated with increased risk of cardiovascular diseases
in later life of both mother and baby [4,5]. Twin studies
have shown that genetic factors account more than 50%
of an individual's susceptibility to pre-eclampsia [6].
Despite intensive research genetic factors predisposing
pre-eclampsia are largely unknown [7,8].
Abnormalities in the angiogenic balance have been pro-
posed to as having a major role in the molecular cascade
causing maternal endothelial dysfunction and systemi-
cally reduced perfusion in pre-eclampsia [9]. Hypoxia-
inducible factor (HIF-1) is a transcriptional activator that
plays important role in physiologic responses to hypoxia,
and the pathophysiology of common human diseases
such as ischemic cardiovascular disease, cancer, pre-
eclampsia and intrauterine growth restriction (IUGR)
[10]. HIF-1 is a heterodimer consisting of an oxygen-regu-
lated HIF1-α subunit and a constitutively expressed HIF1-
β subunit [10]. The HIF-1 heterodimer recognizes HIF-
response elements within the promoter regions of
hypoxia-responsive target genes. More than 100 target
genes that are involved in angiogenesis, vascular tone, glu-
cose metabolism, cell proliferation, cell survival and
apoptosis are known to be regulated by this mechanism
[11]. Under normoxic conditions, the alpha subunit is
rapidly degraded by means of ubiquitination and proteo-
somal degradation [12,13]. HIF1-α protein levels are reg-
ulated by the von Hippel -Lindau protein, which targets
the N-terminal transactivation domain (N-TAD) within
the oxygen-dependent degaradation domain (ODD) of
HIF1-α [12,14].
Two non-synonymous single nucleotide sequence vari-
ants, rs11549465 and rs11549467, in the exon 12 of the
HIF1A  gene cause amino acid substitution within
(rs11549465) or near (rs11549467) the minimal N-ter-
minal transactivation domain (N-TAD) within the ODD
that mediates interactions with the von Hippel-Lindau
protein, which in turn targets HIF1-α for degradation (Fig-
ure 1) [15]. We studied whether these sequence variants,
rs11549465 (c.1744 C>T) that changes residue 582 of
HIF-1α from proline to serine (Pro582Ser) and
rs11549467 (c.1762 G>A) that changes residue 588 of
HIF-1α from alanine to threonine (Ala588Thr) in the
exon 12 of the HIF1A  gene, are associated with pre-
eclampsia.
Structure of the HIF-1α protein, and polymorphisms identified by sequencing the exon 12 of the HIF1A gene Figure 1
Structure of the HIF-1α protein, and polymorphisms identified by sequencing the exon 12 of the HIF1A gene. 
bHLH = basic-helix-loop-helix domain, PAS = Per-Arnt-Sim domain, ODD = oxygen dependent degradation domain, N-TAD = 
N-terminal transactivation domain, C-TAD = C-terminal transactivation domain. Rs11549465 changes residue 582 of HIF-1α 
from proline to serine (P582S), and rs11549467 changes residue 588 of HIF-1α from alanine (A) to threonine (T). Variant 
rs34005929 is a synonymous change of the last nucleotide of codon 580 encoding a leucine (L). Variant changing the last nucle-
otide of codon 600 (T) is predicted to be a silent polymorphism.BMC Medical Genetics 2008, 9:96 http://www.biomedcentral.com/1471-2350/9/96
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Methods
Patients
108 women with pre-eclampsia in their first pregnancy,
and 101 controls with at least one normotensive preg-
nancy were included in this study. This is a retrospective
analysis of stored DNA samples. The study population has
been previously described [16].
Before their first pregnancy, both patients and controls
have been healthy and no evidence of renal or autoim-
mune disease could be detected. Pre-eclampsia was
defined using the following criteria; 1) blood pressure
(BP) level at least 140/90 mmHg, and 2) proteinuria at
least 0.3 g per 24-hour urine collection [17]. The blood
pressure was checked by two measurements with at least 6
hours apart and proteinuria was confirmed after gestation
week 20. Pre-eclampsia was defined as severe in 95
women who also fulfilled one or more of the following
criteria included in the severity predictors of the National
High Blood Pressure Education Working Group: systolic
BP at least 160 mmHg, diastolic BP at least 110 mmHg, or
proteinuria at least 2 g during any 24-hour urine collec-
tion [18].
The blood samples were collected between January 1997
and April 1998 from women who, according to discharge
records of the Helsinki University Central Hospital, had
had severe pre-eclampsia between 1988 and 1998. The
control samples were collected from women with uncom-
plicated pregnancies who gave birth at the Helsinki Uni-
versity Central Hospital. Patients and controls are of
Finnish (Caucasian) origin. This study has been approved
by the local ethical review committee and an informed
consent was obtained from all the study subjects. The clin-
ical characteristics of the patients are presented in Table 1.
Genotyping
Genomic DNA was extracted from 10 ml of peripheral
blood using a phenol-chlorophorm method. PCR ampli-
fication of the exon 12 of the HIF1A gene was performed
using forward and reverse primers 5'-CAGAAGCAAA-
GAACCCAT-3' (F) and 5'-TCAAGAATTTGCGTTAG-3' (R),
described by Resar et al. (2005) [19]. The reaction was
done in a 50 μl volume containing 70 ng genomic DNA,
30 pmol of each primer, 10 mM Tris-HCl, pH 8.8, 1.5 mM
MgCl2, 50 mM KCl and 0.1% Triton X-100, 10 nmol of
each nucleotide (dNTP) and 0.75 U Dynazyme polymer-
ase-enzyme (Finnzymes Oy, Espoo, Finland). Polymerase
chain reaction conditions were as follows: 4 min at 94°C
followed by 35 cycles of denaturation step: 30 s at 94°C;
annealing step: 30 s at 49°C; elongation step: 30 s at
72°C; and final extension for 10 min at 72°C terminated
the reaction after final annealing. Amplifications were
performed in a DNA 2720 Thermal Cycler (ABI, Foster
City, CA, USA).
Sequencing of the PCR amplicons were performed using
Big Dye Terminator kit (version 3.1) supplied by Applied
Biosystems (ABI, Foster City, CA, USA). The reactions
were run on an ABI 3730 capillary sequencer according to
the manufacturer's instructions.
Statistics and study power
The minor allele frequencies of the r rs11549465 and
rs11549467 are 0.092 and 0.018, respectively, in the
CEPH population (Utah residents with ancestry from
northern and western Europe) http://www.hapmap.org.
Our sample size has 80% power to detect a relative risk 2.2
for the rs11549465 variant, and a relative risk 2.7 for the
rs11549467 variant in the HIF1A gene at a significance
level α = 0.05. Statistical analyses were performed using
GraphPad Prism 4 (GraphPad software Inc., CA, USA).
The association between the polymorphisms and pre-
eclampsia was estimated by comparing the frequencies in
the two study groups. The statistical significance of the dif-
ferent proportions was measured using Fisher's exact test.
Parametric and non-parametric tests were used as appro-
priate for the continuous clinical data. Differences were
considered as statistically significant for P values <0.05. To
determine if genotype frequencies deviate from the the
Table 1: Clinical Characteristics
Pre-eclampsia (N = 108) Controls (N = 101)
Variable Mean (95% CI) Mean (95% CI) P
Age (y) 29.5 (28.5, 30.4) 29.9 (28.9.0, 30.9) NS
BMI (kg/m2) 22.6 (22.0, 23.2) 22.6 (21.6, 23.5) NS
Systolic blood pressure (mmHg) 171 (168, 175) 119 (117, 121) <0.0001
Diastolic blood pressure (mmHg) 107 (105, 108) 73 (72, 75) <0.0001
Proteinuria (g/24 h) 7.5 (5.9, 9.1)
Birth weight (SD) -1.5 (-1.7, -1.3) -0.2 (-0.4, -0.1) <0.0001
Weeks of gestation 34.5 (33.7, 35.3) 39.6 (39.4, 39.9) <0.0001
CI = confidence interval
NS = non significantBMC Medical Genetics 2008, 9:96 http://www.biomedcentral.com/1471-2350/9/96
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Hardy-Weinberg Equilibrium (HWE) a Χ2 test was per-
formed http://www.oege.org.
Results
As a result of sequencing exon12 of the HIF1A gene and
the flanking exon-intron boundaries of HIF1A four exonic
sequence variants were detected. All the variants in both
patients and controls were detected in a heterozygous
state. All four SNP genotype frequencies in both patients
and controls were in agreement with Hardy-Weinberg
equilibrium (p > 0.05.)
No statistical differences were shown when comparing the
frequencies of the non-synonymous sequence variants,
rs11549465 and rs11549467 between patients and con-
trols. Table 2 shows locations of the detected variants,
their effect on the protein, and number of alleles in
patients and controls. Numbering of the base positions is
relative to the adenine in the ATG startcodon of the HIF1A
gene.
In addition to two non-synonymous sequence variants,
we found two synonymous sequence variants (Figure 1).
Variant rs34005929 (c.1740 G>A), a synonymous change
of the last nucleotide of codon 580 encoding a leucine,
was detected in two patients but in none of the controls.
Variant c.1800 A>T is changing the last nucleotide of
codon 600 (Thr), and is predicted to be a silent polymor-
phism. This variation was detected in four patients and
two controls. According to our knowledge this sequence
variant has not been reported in public databases.
Discussion
In this study performed in the genetically homogenous
Finnish population, we found that the allele distribution
of the two non-synonymous sequence variants,
rs11549465 (c.1744 C>T, Pro582Ser) and rs11549467
(c.1762 G>A, Ala588Thr), in the exon 12 of the HIF1A
gene was not different between women with pre-eclamp-
tic first pregnancies and controls with normotensive preg-
nancies. We also found two synonymous sequence
variants in the exon 12 of HIF1A  gene: rs34005929
(c.1740 G>A, Leu580Leu) and variant c.1800 A>T
(Thr600Thr) which has not previously been reported in
public databases.
HIF-1α is known to play role in the normal development
and pathology of placenta as a regulator of responses to
hypoxia. Accumulation of HIF-1α protein in the pre-
eclamptic placentas occurs as a consequence of both
increased formation secondary to relative ischemia/
hypoxia and reduced degradation after reperfusion/oxy-
genation due to proteosomal dysfunction [20]. Overex-
pression of HIF-1α protein in placenta contributes to the
dysregulation of numerous genes [21]. Abnormalities in
the angiogenic balance have been proposed to as having a
major role in the molecular cascade causing maternal
endothelial dysfunction and systemically reduced per-
fusion in pre-eclampsia [9], which makes HIF1A an inter-
esting gene in contributing the maternal response to
reduced placental perfusion.
Pre-eclampsia originates in the placenta but the target
organ is maternal endothelium. Endothelial dysfunction,
a central feature in pre-eclampsia, has been suggested to
be a part of a more generalized inflammatory reaction
[22]. Innate immune response has been linked to the
hypoxic response through transcriptional regulation of
HIF-1α by transcription factor NF-κB [23].
Pre-eclampsia increases the risk of future ischemic heart
disease [24]. This could be an inherent propensity in these
women, or vascular damage may have occurred as a con-
sequence of the pre-eclamptic pregnancy. HIF1A is one of
the genes of importance in the pathways mediating the
response to ischemia. The rs11549465 sequence variant
was more common in patients who presented with stable
exertional angina rather than acute myocardial infarction
[25]. These authors suggested that the reduced activity of
the variant form of HIF1A could reduce plaque neovascu-
larization and the risk of intraplaque hemorrhage and of
subsequent acute myocardial infarction [25].
Table 2: Non-synonymous sequence variants within the oxygen-dependent degradation domain of the HIF1A gene with pre-eclamptic 
first pregnancies (N = 108) and women with normotensive pregnancies (N = 101)
Variation Amino acid No. of alleles in cases No. of alleles in controls P-value* OR (95% CI)
rs11549465 (c.1744C>T)
C allele Pro582 208 189 0.26 0.56 (0.23–1.38)
T allele Ser582 8 13
rs11529467 (c.1762G>A)
G allele Ala588 212 199 1.00 1.25 (0.28–5.66)
A allele Thr588 4 3
*Fisher's exact testBMC Medical Genetics 2008, 9:96 http://www.biomedcentral.com/1471-2350/9/96
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The results of the functional studies of the sequence vari-
ants in the HIF1A gene in different tissues as well as, the
effect of these variants in angiogenesis are inconclusive.
The rs11549465 and rs11549467 variants of the HIF1A
gene have been shown to have enhanced transcription
activities in in vitro studies under both normoxic and
hypoxic conditions [26,27]. Rs11549465 variant was
associated with increased tumor microvessel density in
head and neck cancer [26], and in prostate cancer [27].
The expression of some down-stream genes that are under
the transcription control of HIF-1α ( LDH-5, VEGF,
GLUT1) was not increased in the presence of the
rs11549465 variant in non-small cell lung cancer samples
studied by immunohistochemistry [28]. In the presence
of rs11549465 variant the formation of collaterals in
patients with ischemic heart disease was impaired [19].
To the best of our knowledge this is the first study to inves-
tigate whether the two non-synonymous sequence vari-
ants that lie within or near the N-TAD within the ODD in
the exon 12 of the maternal HIF1A gene are associated
with the pre-eclamptic phenotype.
These sequence variants are interesting because polymor-
phisms that reduce the activity of HIF-1α as a transcrip-
tional activator could underlie pre-eclampsia by causing
inadequate placental vascularisation in the early preg-
nancy which later leads to hypoxia in the placenta. We are
not aware of studies comparing the frequency of these
sequence variants between the pre-eclamptic placentas
and placentas from normotensive pregancies, or studies
measuring the HIF-1α levels in placentas heterozygous of
homozygous for these sequence variants.
This retrospective study has several limitations. First, we
did not have fetal DNA samples. Consequently, we were
neither able to study the effect of fetal/placental genotype
nor the maternal fetal genotype interaction. The other
limitation is inadequate statistical power to detect small
genotypic effects. Under a dominant model, the sample
size provides 80% power to detect a genotype relative risk
over 2.2, which is much higher than the risk conferred by
the majority of susceptibility genes detected to date for
complex disorders. For detection of small genotypic
effects studies in larger sample sets are warranted. Further
studies are also warranted to elucidate effects of the func-
tional polymorphisms in HIF1A on the pathogenesis of
maternal and placental pre-eclampsia. Pre-eclampsia
involves complex interaction between placentation, vas-
cular function and maternal metabolism. Thus, research
and recognition of genes, such as HIF1A, and thereby bio-
chemical components critical for such interactions
increase our understanding of the molecular mechanisms
leading from cellular hypoxia to metabolic changes.
Conclusion
Our data suggest that the sequence variants in the exon 12
of the HIF1A gene are not associated with pre-eclampsia
in the Finnish population. The study has inadequate sta-
tistical power to detect small genotypic effects. Therefore,
this gene should be assessed in bigger studies. Further
studies are also warranted to elucidate possible fetal gen-
otypic effects.
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